Ultrasound Contrast Agent Patents (Class 424/9.5)
  • Patent number: 11969483
    Abstract: Mesoporous silica nanoparticles (MSNs) that may be useful as ultrasound contrast agents for detecting and treating bladder cancer are described herein. The MSNs include a lanthanide, a fluorophore, and an agent detectable by ultrasound.
    Type: Grant
    Filed: October 13, 2020
    Date of Patent: April 30, 2024
    Assignee: NANOMEDTRIX, LLC
    Inventors: Joe G. Assouline, Sean K. Sweeney
  • Patent number: 11903767
    Abstract: Aspects of the invention relate to composite markers that employ a gel carrier to carry two or more contrast materials, each detectable by a detection modality different than one another. Kits and methods for forming these composite markers and methods of marking a target site in a mammalian subject employing these composite markers are also discussed herein.
    Type: Grant
    Filed: November 24, 2020
    Date of Patent: February 20, 2024
    Assignee: VIEW POINT MEDICAL, INC.
    Inventors: William Blair, Mike Jones, John Merritt
  • Patent number: 11771870
    Abstract: The techniques of this disclosure generally relate to a vector flush sizing catheter that is used initially to disperse contrast and measure a length of a main vessel using radiopaque measuring markers of the catheter. Subsequently, the vector flush sizing catheter is used to guide and introduce another endovascular device into the main vessel. By using the vector flush sizing catheter for both procedures, the exchange of catheters, the complexity of the procedure, and the associated risks are minimized.
    Type: Grant
    Filed: February 7, 2022
    Date of Patent: October 3, 2023
    Assignee: Medtronic Vascular, Inc.
    Inventor: Christopher J. Della Vecchia
  • Patent number: 11633362
    Abstract: The present invention relates generally to pharmaceutical formulations. Particularly, the present invention relates to a new delivery system for delivery of medical components to the lungs, and its utility in the fields of pharmaceutical formulation, drug delivery, medicine and diagnosis.
    Type: Grant
    Filed: September 5, 2018
    Date of Patent: April 25, 2023
    Assignee: SINTEF TTO AS
    Inventors: Yrr Mørch, Einar Sulheim
  • Patent number: 11045559
    Abstract: The present invention relates to a nanocomposite for detecting hydrogen sulfide; a method for preparing the same; a novel reactive fluorogenic compound to be used in the method; a kit for detecting hydrogen sulfide comprising the nanocomposite; and a method for providing information for the diagnosis of a disease, which causes abnormal secretion of hydrogen sulfide, by using the nanocomposite.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: June 29, 2021
    Assignee: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Sehoon Kim, Myung Kim, Young Hun Seo, Jungyun Heo, Youngsun Kim
  • Patent number: 10961547
    Abstract: Described are nanoparticulates comprising a metallic nanoparticle core and a peptide coating or shell encapsulating the nanoparticle core and being covalently bonded thereto. The coating is formed from a plurality of branched, amphipathic peptides, each comprising a polar/positively charged C-terminal segment, a branch point, and two hydrophobic N-terminal segments extending from the branch point. Methods of forming and using the nanoparticulates are also described. When a plurality of first and second peptides are added sequentially to the nanoparticle core, the peptides they self-assemble to form an interlocking peptide network bilayer where the respective hydrophobic segments of the peptides form beta-sheet structures in which the opposed sequences interlock to form a zipper-like structure in three dimensions.
    Type: Grant
    Filed: November 4, 2015
    Date of Patent: March 30, 2021
    Assignee: Kansas State University Research Foundation
    Inventors: John M. Tomich, Pinakin R. Sukthankar
  • Patent number: 10918718
    Abstract: The invention disclosed herein relates to a method of cavitation-induced delivery of a therapeutic or diagnostic agent to a human or animal subject. In particular the invention provides an agent for use in a method of diagnosis or treatment of a human or animal subject, the method comprising exposing the subject to ultrasound, wherein the agent comprises a therapeutic or diagnostic component which is covalently bound to a dense component, the dense component having a density greater than that of the therapeutic or diagnostic component, and wherein either the dense component is a cavitation initiator or the method comprises administering to the subject a further agent which is a cavitation initiator. Binding of the dense component enhances cavitation-induced transport of the therapeutic or diagnostic component.
    Type: Grant
    Filed: October 21, 2014
    Date of Patent: February 16, 2021
    Assignee: Oxsonics Limited
    Inventors: Steven Mo, Robert Crispin Carlisle, Leonard W. Seymour, Constantin-Cassios Coussios
  • Patent number: 10918605
    Abstract: A method for preparing a suspension of size-controlled microparticles stabilized by a layer of amphiphilic material. The method, which may be applied to preparations using microfluidic techniques, comprises controlling the temperature of the microparticles during the preparation process and preferably while collecting the formed microparticles.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: February 16, 2021
    Assignee: Bracco Suisse SA
    Inventors: Tim Segers, Peter Frinking, Anne Lassus, Philippe Bussat, Emmanuel Gaud, Samir Cherkaoui
  • Patent number: 10583208
    Abstract: Provided herein are improved methods for preparing phospholipid formulations including phospholipid UCA formulations.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: March 10, 2020
    Assignee: Lantheus Medical Imaging, Inc.
    Inventors: Simon P. Robinson, Robert W. Siegler, Nhung Tuyet Nguyen, David C. Onthank, Tarakeshwar Vishwanath Anklekar, Charles Chester Van Kirk
  • Patent number: 10220104
    Abstract: Provided herein are improved methods for preparing phospholipid formulations including phospholipid UCA formulations.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: March 5, 2019
    Assignee: Lantheus Medical Imaging, Inc.
    Inventors: Simon P. Robinson, Robert W. Siegler, Nhung Tuyet Nguyen, David C. Onthank, Tarakeshwar Vishwanath Anklekar, Charles Chester Van Kirk
  • Patent number: 9913919
    Abstract: Provided herein are improved methods for preparing phospholipid formulations including phospholipid UCA formulations.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: March 13, 2018
    Assignee: Lantheus Medical Imaging, Inc.
    Inventors: Simon P. Robinson, Robert W. Siegler, Nhung Tuyet Nguyen, David C. Onthank, Tarakeshwar Vishwanath Anklekar, Charles Chester Van Kirk
  • Patent number: 9618445
    Abstract: The present application discloses optical microscopy systems and related method that use modulation techniques and contrast agents to enable the systems to detect nonlinear photoacoustic signals with high spectrum sensitivity and frequency selectivity for imaging. A laser beam is amplitude modulated for pure sinusoidal modulation using either the loss modulation technique or the single light amplitude modulation technique. The sample used in the invention is an endogenous contrast agent by itself or is treated by at least one exogenous contrast agent to produce or enhance photoacoustic effect induced by multi-photon absorption. The modulated laser beam is focused via a focusing device onto a sample which absorbs multiple photons simultaneously and generates ultrasonic (acoustic) waves via nonlinear photoacoustic effect. The ultrasonic waves are received and transformed into electrical signals and the frequency signals within the electrical signals are detected and recorded to create images.
    Type: Grant
    Filed: December 9, 2013
    Date of Patent: April 11, 2017
    Assignee: National Taiwan University
    Inventors: Chi-Kuang Sun, Yu-Hung Lai, Chieh-Feng Chang, Szu-Yu Lee
  • Patent number: 9561293
    Abstract: This disclosure relates to a method for preparing organic microbubble complex particles including sonicating an aqueous solution including a graphene compound and an amphiphilic material in the presence of a gas, a method for preparing organic microbubble complex particles including injecting an aqueous solution including a graphene compound and an amphiphilic material into a microchannel, and an organic microbubble complex particle including a core part including at least one gas selected from the group consisting of an inert gas and carbon dioxide, and a shell layer including a graphene compound and an amphiphilic material, and an ultrasound contrast agent including the organic microbubble complex particles.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: February 7, 2017
    Assignee: SNU R&DB FOUNDATION
    Inventors: Kookheon Char, Saibom Park
  • Patent number: 9364569
    Abstract: Method for preparing a lyophilized matrix and, upon reconstitution of the same, a respective injectable contrast agent comprising a liquid aqueous suspension of gas-filled microbubbles stabilized predominantly by a phospholipid. The method comprises preparing an emulsion from an aqueous medium, a phospholipid and a water immiscible organic solvent. The emulsion is then freeze-dried and subsequently reconstituted in an aqueous suspension of gas-filled microbubbles. The method allows to obtain suspensions comprising microbubbles having a relatively small diameter and a narrow size distribution.
    Type: Grant
    Filed: February 3, 2004
    Date of Patent: June 14, 2016
    Assignee: Bracco Suisse S.A.
    Inventors: Michel Schneider, Philippe Bussat, Feng Yan, Christian Guillot
  • Publication number: 20150147278
    Abstract: The present invention provides a prophylactic or therapeutic agent for various malignant tumors, including currently intractable solid tumors, which contains a novel antibody having the ability to bind to human LAT1/CD98 and inducing antibody-dependent cellular cytotoxicity specifically against cancer cells as an active ingredient.
    Type: Application
    Filed: December 5, 2014
    Publication date: May 28, 2015
    Applicants: Kinki University, Link Genomics, Inc.
    Inventors: Takashi Masuko, Shinichiro Niwa, Hidemi Hayashi, Dai Ogura, Takayuki Shindou
  • Publication number: 20150147276
    Abstract: The invention provides compositions and methods for targeted controlled drug release. The compositions and methods can be used for treating or imaging vascular stenosis, stenotic lesions, occluded lumens, embolic phenomena, thrombotic disorders and internal hemorrhage.
    Type: Application
    Filed: June 7, 2013
    Publication date: May 28, 2015
    Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Donald E. Ingber, Netanel Korin, Mathumai Kanapathipilai, Oktay Uzun, Anne-Laure Papa
  • Patent number: 9040022
    Abstract: The present invention relates to compositions and methods for treating diseases and disorders including cancer and various other angiogenic-dependent diseases, vascular malfunctions, arteriovenous malformations (AVM), hemorrhagic processes and treatment of pain, in particular tumor-related pain by drug delivery and/or therapeutic embolization using microspheres. More particularly the invention relates to microspheres containing non-ionic contrast agents, to compositions comprising these microspheres, as well as methods for preparing and using such compositions for embolization therapy. The invention further relates to compositions and methods using detectable microspheres for targeted drug delivery, irrespective of whether embolization is also needed.
    Type: Grant
    Filed: February 14, 2014
    Date of Patent: May 26, 2015
    Assignee: Biosphere Medical, S.A.
    Inventor: Philippe Reb
  • Publication number: 20150132227
    Abstract: Disclosed are compositions and methods for related to echogenic contrast agents. Also disclosed are methods and compositions for diagnosing eosinophilic esophagitis in a subject. Also disclosed are methods for producing a medical image of a tissue. Also disclosed are methods of monitoring the progression of eosinophilic esophagitis in a subject before, during, and after treatment.
    Type: Application
    Filed: April 18, 2013
    Publication date: May 14, 2015
    Inventors: Leonard F. Pease, Hedieh Saffari, Kathryn Peterson, Kristin Leiferman, Anne Kennedy, Russell Morris Condie, Gerald Gleich
  • Publication number: 20150125398
    Abstract: The invention provides particles useful for sequential imaging or for diagnostics or therapeutics. Disclosed is a method to image diagnostic or therapeutic cells in a mammal, comprising: introducing to a mammal a composition comprising mammalian cells comprising mesoporous silica nanoparticles (MSNs) comprising a lanthanide, a fluorophore and an agent detectable by ultrasound; applying ultrasound and/or a magnetic field to the mammal and recording ultrasound and/or magnetic resonance images that include the MSNs; and detecting the presence, location or amount of the MSNs in the mammal.
    Type: Application
    Filed: March 13, 2013
    Publication date: May 7, 2015
    Inventors: Jose G Assouline, Brian G. Trewyn, Sean K Sweeney, Kapil Kandel
  • Publication number: 20150118161
    Abstract: The present invention concerns an aqueous ultrasound contact fluid comprising a pharmaceutical grade triglyceride and a pharmaceutically acceptable emulsifier and the use of said ultrasound contact fluid in an intraoperative or interventional ultrasound imaging procedure.
    Type: Application
    Filed: May 8, 2013
    Publication date: April 30, 2015
    Applicant: Sinvent AS
    Inventors: Tormod Selbekk, Geirmund Unsgård
  • Publication number: 20150093332
    Abstract: A tumor-targeting multi-mode imaging and analyzing method for living body based on gold nanoclusters can include incubating the relevant cells with chloroauric acid and the salt solution thereof with certain concentration under physiological conditions, thereby generating gold nanoclusters. After, real-time non-invasive fluorescence imaging, Raman imaging and/or ultrasonic imaging can be used to image the tumor tissue.
    Type: Application
    Filed: December 11, 2014
    Publication date: April 2, 2015
    Inventors: Xuemei Wang, Jianling Wang, Qiwei Li, Hui Jiang
  • Publication number: 20150093336
    Abstract: The disclosure relates to immunoglobulin single variable domains directed against human macrophage mannose receptor (MMR) and their uses in the field of oncology. More specifically, it concerns immunoglobulin single variable domains, including single-domain antibodies (sdAbs), against human MMR and their use in targeting and in vivo imaging of tumor-associated macrophages, with applications in the field of cancer diagnostics and therapeutics and monitoring of the disease.
    Type: Application
    Filed: March 15, 2013
    Publication date: April 2, 2015
    Inventors: Jo Van Ginderachter, Patrick De Baetselier, Nick Devoogdt, Tony Lahoutte, Damya Laoui, Kiavash Movahedi, Geert Raes, Steve Schoonooghe
  • Patent number: 8992887
    Abstract: The present invention relates to an image enhancing composition for the enhancement of contrast in a body cavity, wherein the viscosity of the composition is between 2000 and 4000 mPa·sec. It also relates to a method for enhancing contrast of an image of a body cavity, which method involves introducing one single small aliquot of an image enhancing composition into the body cavity. In another aspect, the present invention provides a high contrast image of a body cavity obtained by the method of the invention, in particular a 3-dimensional high contrast image.
    Type: Grant
    Filed: July 14, 2005
    Date of Patent: March 31, 2015
    Assignee: GynaecologIQ B.V.
    Inventors: Mark Hans Emanuel, Niek Exalto
  • Patent number: 8986655
    Abstract: PSMA ligands, compositions, and methods therefore are disclosed where the ligand is a peptide having the sequence X1X2CVEVX3QNSCX4X5 where X1-X5 are independently a natural or non-natural amino acid or a peptide having the sequence CALCEFLG [SEQ ID NO: 1]. Especially preferred aspects include diagnostic reagents for detection and/or quantification of PSMA in a sample, therapeutic reagents, and diagnostic imaging reagents.
    Type: Grant
    Filed: May 19, 2010
    Date of Patent: March 24, 2015
    Assignee: The Regents of the University of California
    Inventors: Gregory A. Weiss, Jessica Arter, Juan E. Diaz
  • Publication number: 20150064110
    Abstract: The present invention relates to a method for preparing beads comprising imaging agent. The present invention further provides beads highly useful for medical imaging.
    Type: Application
    Filed: February 22, 2013
    Publication date: March 5, 2015
    Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite Paris Diderot - Paris 7, Univ Paris XIII Paris-Nord Villetaneuse
    Inventors: Sidi Mohammed Derkaoui, Catherine Le Visage, Thomas Bonnard, Didier LeTourneur, Jean-Michel Serfaty
  • Publication number: 20150056133
    Abstract: The present invention relates to CX3CR1-targeting imaging agents and their use in treatment and diagnosis of diseases. Single domain CX3CR1-targeting polypeptides linked to detection labels and their use in in vivo imaging of atherosclerotic plaques are described. The CX3CR1-targeting imaging agents are useful in the treatment and diagnosis of CX3CR1-mediated diseases including atherosclerosis.
    Type: Application
    Filed: August 20, 2014
    Publication date: February 26, 2015
    Inventors: Alisa K. WATERMAN, Nick Mark Devoogdt, Tony Lahoutte, Matthias SCHNEIDER, Sanjaya SINGH, Cedric Jozef Néotère VERVERKEN
  • Patent number: 8961936
    Abstract: One aspect of the present invention relates to a method of ultrasonography, utilizing a gel comprising a reverse phase polymer which facilitates the transmission of high-frequency sound waves. Further, the inherent properties of the reverse phase polymer result in increased adhesion at higher temperatures, thereby helping to maintain the desired position of the ultrasound probe until the user intends to adjust the probe's position. In certain embodiments, the method is utilized in a medical procedure in which stability of an ultrasound probe or transducer in an intended desired position can improve the outcome or increase the efficiency of the procedure. In certain embodiments, the gel further comprises an additive to increase the ultimate adhesion of the gel. In still other embodiments, the gel can be used on the skin, on a protective sheath encasing an ultrasound probe, or between the sheath and the probe, or any or all of them.
    Type: Grant
    Filed: September 22, 2011
    Date of Patent: February 24, 2015
    Assignee: Genzyme Corporation
    Inventors: Christopher Wiley, John A. Merhige
  • Patent number: 8961926
    Abstract: The invention relates to a method for targeting an imaging agent to cells of an animal to detect localized infections. More particularly, localized infections are detected by targeting imaging agents to inflammatory cells having receptors for a vitamin by using vitamin-imaging agent conjugates.
    Type: Grant
    Filed: May 23, 2008
    Date of Patent: February 24, 2015
    Assignee: Purdue Research Foundation
    Inventors: Philip Stewart Low, Walter Anthony Henne, Jr., Bindu Varghese, Ryan Rothenbuhler
  • Patent number: 8957215
    Abstract: The present invention relates to novel heteroaryl substituted benzothiazole derivatives, precursors thereof, and therapeutic uses for such compounds, having the structural formula (I) below: and to their pharmaceutically acceptable salt, compositions and methods of use. Furthermore, the invention relates to novel heteroaryl substituted benzothiazole derivatives that are suitable for imaging amyloid deposits in living patients, their compositions, methods of use and processes to make such compounds. More specifically, the present invention relates to a method of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease as well as measuring clinical efficacy of Alzheimer's disease therapeutic agents.
    Type: Grant
    Filed: April 23, 2012
    Date of Patent: February 17, 2015
    Assignee: Navidea Biopharmaceuticals, Inc.
    Inventors: Ylva Gravenfors, Catrin Jonasson, Jonas Malmstrom, Gunnar Nordvall, David Pyring, Can Slivo, Daniel Sohn, Peter Strom, David Wensbo
  • Patent number: 8939910
    Abstract: A hydrogel marker is placed under stress during its curing stage, in one embodiment, by application of an externally applied force. The stress may also be induced during or after the dehydration process. The direction of the externally applied force increases the length, width, depth, or radial extent of the marker. The elastic limit of the marker is exceeded when the external force is applied so that the marker substantially retains its stressed size and shape when the externally applied force is removed. When the stretched or otherwise deformed dehydrated marker is hydrated, it substantially returns to the configuration it had prior to its dehydration and prior to the application of the externally applied force.
    Type: Grant
    Filed: March 28, 2006
    Date of Patent: January 27, 2015
    Assignee: Devicor Medical Products, Inc.
    Inventor: John S. Fisher
  • Publication number: 20150023880
    Abstract: The present invention describes processes for the preparation of a lipid blend and a uniform filterable phospholipid suspension containing the lipid blend, such suspension being useful as an ultrasound contrast agent.
    Type: Application
    Filed: February 24, 2014
    Publication date: January 22, 2015
    Applicant: Lantheus Medical Imaging, Inc.
    Inventors: Poh K. Hui, John E. Bishop, Eleodoro S. Madrigal, JR.
  • Patent number: 8936809
    Abstract: A method for treating prostate related diseases in a subject, the method comprising i) optionally administering to subject an initial boost dose of one or more active substances and/or prodrugs, and ii) administering locally into the prostate a controlled release pharmaceutical composition comprising one or more active substances in a biodegradable ceramic carrier. The biodegradable hydrating ceramic may be selected from the group consisting of non-hydrated or hydrated calcium sulphate, calcium phosphate, calcium carbonate, calcium fluoride, calcium silicate, magnesium sulphate, magnesium phosphate, magnesium carbonate, magnesium fluoride, magnesium silicate, barium sulphate, barium phosphate, barium carbonate, barium fluoride, barium silicate, or mixtures thereof. In a specific embodiment, the biodegradable hydrating ceramic is non-hydrated or hydrated calcium sulphate.
    Type: Grant
    Filed: March 31, 2006
    Date of Patent: January 20, 2015
    Assignee: Lidds AB
    Inventors: Hans Lennernäs, Bo Lennernäs, Jonas Hugosson, Niklas Axén
  • Patent number: 8932562
    Abstract: Provided herein are animals expressing light-responsive opsin proteins in the basal lateral amygdala of the brain and methods for producing the same wherein illumination of the light-responsive opsin proteins causes anxiety in the animal. Also provided herein are methods for alleviating and inducing anxiety in an animal as well as methods for screening for a compound that alleviates anxiety in an animal.
    Type: Grant
    Filed: November 4, 2011
    Date of Patent: January 13, 2015
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Karl Deisseroth, Kay Tye, Lief Fenno
  • Patent number: 8926948
    Abstract: Provided are a preparation process of a diagnostic or therapeutic agent having a step of adding, to a first fine emulsion having a particle size of 0.5 ?m or less prepared by applying a predetermined pressure to a first mixture containing a first hydrophobic compound, an emulsifying agent, and an aqueous phase, a second hydrophobic compound compatible with the first hydrophobic compound, thereby preparing a second mixture; and a step of stirring and shaking the second mixture in a hermetically sealed state, thereby embedding the second hydrophobic compound in the first fine emulsion to prepare a second fine emulsion having a particle size of 0.5 ?m or less; a diagnostic or therapeutic agent prepared by the process; and an apparatus for carrying out the process.
    Type: Grant
    Filed: June 27, 2008
    Date of Patent: January 6, 2015
    Assignee: Hitachi, Ltd.
    Inventors: Rei Asami, Kenichi Kawabata
  • Publication number: 20140363377
    Abstract: The invention provides compositions and method for delivering a therapeutic or diagnostic agent to a disease site in a mammal, the method comprising administering to the mammal a therapeutically or diagnostically effective amount of a pharmaceutical composition, wherein the pharmaceutical composition comprises the therapeutic or diagnostic agent coupled to a Procaspase 8 polypeptide and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: June 18, 2014
    Publication date: December 11, 2014
    Inventor: Isabella TAI
  • Publication number: 20140363378
    Abstract: Disclosed are compositions that contain a plurality of biocompatible self-assembling molecules that transform from isolated molecules or spherical micelles in the circulation into cylindrical nanofibers in the acidic extracellular environment of tumors which can be used to achieve a higher relative concentration of imaging, drug delivery, or radiotherapeutic agents at the tumor site compared to non-tumor tissues. This transition is rapid and reversible, indicating the system is in thermodynamic equilibrium.
    Type: Application
    Filed: February 1, 2013
    Publication date: December 11, 2014
    Inventors: Joshua E. Goldberger, Michael F. Tweedle
  • Patent number: 8901276
    Abstract: The present invention is directed to peptide reagents, methods for detecting colon pre-cancer (dysplasia with non-polypoid or polypoid morphology) or cancer using the peptide reagents, and methods for targeting pre-cancerous or cancerous colon cells using the peptide reagents.
    Type: Grant
    Filed: December 19, 2011
    Date of Patent: December 2, 2014
    Assignee: The Regents of the University of Michigan
    Inventors: Thomas D. Wang, Sharon Miller, Bishnu Joshi
  • Publication number: 20140348752
    Abstract: The present invention provides methods of treating LAL deficiency comprising administering to a mammal a therapeutically effective amount of lysosomal acid lipase with an effective dosage frequency. Methods of improving growth and liver function, increasing LAL tissue concentration, and increasing LAL activity in a human patient suffering from LAL deficiency are also provided.
    Type: Application
    Filed: December 10, 2013
    Publication date: November 27, 2014
    Inventor: Anthony Quinn
  • Publication number: 20140335024
    Abstract: Nanocarriers and methods of preparation and use of nanocarriers are presented. In some embodiments, a nanocarrier composition comprises an organic liquid comprising a plurality of nanoparticles dispersed therein; and a coating material disposed around the exterior surface of the organic liquid. Biological tissue may be imaged or treated by coming into contact with a nanocarrier composition, and, at least in some embodiments, irradiated.
    Type: Application
    Filed: July 29, 2014
    Publication date: November 13, 2014
    Inventors: Stanislav Emelianov, Katheryne Wilson, Kimberly Homan
  • Patent number: 8883124
    Abstract: Fullerenes, when irradiated with electromagnetic radiation, generate acoustic waves. A photoacoustic tomography method using a material comprising fullerenes is disclosed that includes irradiating the material with a radiation beam such as a laser. The resultant photoacoustic effect produced by the material is detected by at least one detector. A photoacoustic tomography system using a material comprising fullerenes is also described.
    Type: Grant
    Filed: October 31, 2008
    Date of Patent: November 11, 2014
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: Vijay Krishna, Brij M. Moudgil, Benjamin L. Koopman, Stephen Grobmyer, Iwakuma Nobutaka, Qiang Wang, Qizhi Zhang, Huabei Jiang, Parvesh Sharma, Amit Kumar Singh
  • Publication number: 20140286864
    Abstract: The present invention provides polypeptides, peptide dimer, and multimeric complexes comprising at least one binding moiety for KDR or VEGF/KDR complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a KD<1 ?M), and dimer and multimeric constructs comprising these polypeptides.
    Type: Application
    Filed: December 17, 2013
    Publication date: September 25, 2014
    Applicants: Bracco Suisse SA, Dyax Corp.
    Inventors: AARON K. SATO, DANIEL J. SEXTON, DANIEL T. DRANSFIELD, ROBERT CHARLES LADNER, CHRISTOPHE ARBOGAST, PHILIPPE BUSSAT, HONG FAN, SUDHA KHURANA, KAREN E. LINDER, EDMUND R. MARINELLI, PALANIAPPA NANJAPPAN, ADRIAN D. NUNN, RADHAKRISHNA K. PILLAI, SIBYLLE POCHON, KONDAREDDIAR RAMALINGAM, AJAY SHRIVASTAVA, BO SONG, ROLF E. SWENSON, MATHEW A. VON WRONSKI, FENG YAN
  • Publication number: 20140286862
    Abstract: The present application provides an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein (for example, PSA or hK2) for use in the treatment of prostate cancer, and a method for the treatment of prostate cancer in a patient, the method comprising the step of administering a therapeutically effective amount of an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein to the patient.
    Type: Application
    Filed: October 26, 2012
    Publication date: September 25, 2014
    Inventors: Sven-Erik Strand, Amanda Thuy Tran, Sven-Niklas Anders Axelsson
  • Patent number: 8821836
    Abstract: The invention provides SPARC and Albumin binding peptides for the targeting of disease sites, such as tumors, with therapeutic and diagnostic agents. In particular, compositions comprising SPARC binding peptide-Antibody Fc domain fusion proteins and methods of their use are disclosed.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: September 2, 2014
    Assignee: Abraxis BioScience, LLC
    Inventor: Vuong Trieu
  • Publication number: 20140243664
    Abstract: Provided herein are nanobubbles designed for use in ultrasound-mediated ablation of cancer cells. The nanobubbles undergo ultrasound-mediated cavitation at an ablation threshold which is significantly decreased, relative to standard ultrasound-mediated treatment of cancer cells. In exemplary embodiments, the nanobubbles comprise an amphiphilic ABC triblock copolymer, wherein block A comprises a hydrophilic polymer, block B comprises a crosslinking polymer, and block C comprises a hydrophobic copolymer comprising (i) methyl methacrylate (MMA) and (ii) a fluorinated monomer, wherein the fluorinated monomer is present in the hydrophobic copolymer of block C at 25 mole percent or less. Related treatment and diagnostic methods, as well as materials relating to the nanobubbles are provided herein. Methods of making a random copolymer are furthermore provided herein.
    Type: Application
    Filed: October 10, 2012
    Publication date: August 28, 2014
    Inventors: Mohamed El-Sayed, Yasemin Yuksel Durmaz
  • Patent number: 8815212
    Abstract: Nanocarriers and methods of preparation and use of nanocarriers are presented. In some embodiments, a nanocarrier composition comprises an organic liquid comprising a plurality of nanoparticles dispersed therein; and a coating material disposed around the exterior surface of the organic liquid. Biological tissue may be imaged or treated by coming into contact with a nanocarrier composition, and, at least in some embodiments, irradiated.
    Type: Grant
    Filed: March 21, 2012
    Date of Patent: August 26, 2014
    Assignee: Board of Regents, The University of Texas System
    Inventors: Stanislav Emelianov, Katheryne Wilson, Kimberly Homan
  • Publication number: 20140227173
    Abstract: Provided are methods for treating cancer in a patient, comprising administering to a patient in need thereof a therapeutically effective regimen, the regimen comprising administering a gamma-secretase inhibitor, wherein the regimen results in a reduction in the cancer cell population in the patient. In some embodiments of the methods, the therapeutically effective regimen stabilizes, reduces or eliminates the cancer stem cell population. Also provided are compounds of the formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, and X are as herein described.
    Type: Application
    Filed: February 6, 2014
    Publication date: August 14, 2014
    Applicant: The Johns Hopkins University
    Inventors: Charles Eberhart, Xing Fan, Anirban Maitra
  • Publication number: 20140205542
    Abstract: Disclosed are compositions, methods and kits to control bleeding through the use of an internal occluder based on polymeric solutions, including use of reverse thermosensitive polymers in nephron-sparing surgeries, which produces a completely bloodless surgical field, allowing speedy resection. In certain embodiments, after a certain amount of time, the flow gradually resumes, with no apparent adverse consequences to the kidney. In certain embodiments, return of blood flow may be accelerated by cooling the kidney. The compositions, methods and kits for perfusive organ hemostasis can also be used to simplify or to enable other organ surgeries or interventional procedures, including liver surgery, prostate surgery, brain surgery, surgery of the uterus, spleen surgery and any surgery on any highly vascularized organs.
    Type: Application
    Filed: March 25, 2014
    Publication date: July 24, 2014
    Applicants: Lahey Clinic, Inc., Genzyme Corporation
    Inventors: Jean-Marie Vogel, James A. Wilkie, Peter N. Madras
  • Publication number: 20140200450
    Abstract: The application discloses the use of an aqueous composition comprising a thickener, and an antiseptic compound or a pharmaceutical acceptable salt thereof as an ultrasonic couplant spray. An ultrasonic couplant spray comprising starch, and an antiseptic compound or a pharmaceutical acceptable salt thereof is also disclosed. Furthermore, the present application relates to a kit comprising a composition according to the present application and spray device.
    Type: Application
    Filed: June 21, 2012
    Publication date: July 17, 2014
    Applicant: Angioclinic AG
    Inventor: Johann Christof Ragg
  • Patent number: 8753620
    Abstract: According to an aspect of the invention, injectable bulking compositions are provided which contain the following: (a) fibers that are configured to prevent migration to locations in the body remote from the injection site, for example, because they have a minimum length that is sufficiently large to prevent migration of the fibers and/or because they have surface features that stimulate host tissue response to lock the fibers in position and (b) a carrier in an amount effective to render the composition injectable.
    Type: Grant
    Filed: August 16, 2012
    Date of Patent: June 17, 2014
    Assignee: Boston Scientific Scimed, Inc.
    Inventors: Jianmin Li, Michael Madden
  • Publication number: 20140161726
    Abstract: Methods and suspensions are provided that are useful for preparing readily reconstitutable, dry compositions of micro- or nanospheres. The dry compositions find use in diagnostic applications such as ultrasonic imaging. The suspension includes as key ingredients one or both of t-butyl alcohol and/or an amorphous sugar (or mixture of amorphous sugar) in specified amounts that reduce aggregation of the particles comprising the suspension.
    Type: Application
    Filed: December 12, 2012
    Publication date: June 12, 2014
    Inventors: Thomas B. Ottoboni, Robert E. Short